Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: adalimumab

A Novel Study Compared the Effectiveness of Adalimumab with Tofacitinib in RA

Samantha C. Shapiro, MD  |  August 17, 2023

Your patient with rheumatoid arthritis (RA) isn’t responding well enough to methotrexate, and you both agree it’s time to consider a biologic or targeted synthetic disease-modifying anti-rheumatic drug (DMARD). But which one should you choose? In a treat-to-target era, we’re fortunate to have a variety of RA therapies at our disposal. Clinical practice guidelines from…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:adalimumabDisease-modifying antirheumatic drugs (DMARDs)Rheumatoid Arthritis (RA)Tofacitinib

First Biosimilar to Adalimumab (Humira) Enters the U.S. Market After Years of Legal Battles

Michele B. Kaufman, PharmD, BCGP  |  January 31, 2023

After years of legal disputes between drug makers, adalimumab-atto (Amjevita) biosimilar to adalimumab (Humira) is now available in the U.S. to treat rheumatoid arthritis and other diseases. Adalimumab-atto is the first of several biosimilars to adalimumab expected to become available in the U.S. in 2023.

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:adalimumabadalimumab-attoBiosimilarsFDALegalPsA Resource CenterPsoriatic ArthritisU.S. Food and Drug Administration (FDA)

FDA Approves First Interchangeable Biosimilar to Adalimumab, Plus a Combination Drug Approved

Michele B. Kaufman, PharmD, BCGP  |  November 17, 2021

Cyltezo (adalimumab-adbm) may be interchanged for Humira (adalimumab) for all indications, according to an October decison by the FDA. The FDA has also approved a new combination of celecoxib and tramadol for pain management.

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:adalimumabadalimumab-adbmBiosimilarscelecoxib (Elyxyb)interchangeabilityPain Managementtramadol

Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis

Vanessa Caceres  |  October 14, 2021

As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis fac­tor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medi­cine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:adalimumabPsoriatic Arthritisupadacitinib

Upadacitnib for RA: Researchers Compared Upadacitinib with Placebo & Adalimumab in Patients with RA & an Inadequate Response to Methotrexate

Vanessa Caceres  |  March 9, 2021

In phase 3 clinical trial, upadacitnib proved superior to placebo and adalimumab in improving the signs and symptoms of RA in patients on stable background methotrexate.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2020ACR Convergence 2020 – RAadalimumabjakinibupadacitinib

Oxford University to Study Adalimumab as Potential COVID-19 Treatment

Josephine Mason & Kate Kelland  |  September 30, 2020

LONDON (Reuters)—Oxford University said on Wednesday it will study whether the prescription medicine, adalimumab (Humira), is an effective treatment for COVID-19 patients—the latest effort to repurpose existing drugs as potential coronavirus therapies. Adalimumab, which is sold by AbbVie, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. Recent studies have shown…

Filed under:Drug Updates Tagged with:adalimumabCOVID-19

FDA Approves the Biosimilar Hadlima (Adalimumab-bwwd)

Michele B. Kaufman, PharmD, BCGP  |  September 16, 2019

Hadlima (adalimumab-bwwd), which is biosimilar to adalimumab, is now FDA approved to treat multiple autoimmune diseases…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumab-bwwdFDAFDA approvalHadlimaU.S. Food and Drug Administration (FDA)

Adalimumab for JIA-Associated Uveitis: 5-Year Follow-up

Lara C. Pullen, PhD  |  July 10, 2019

A five-year study in patients with juvenile idiopathic arthritis-associated uveitis found drug-induced disease remission did not persist once adalimumab was stopped after long-term treatment.

Filed under:ConditionsOther Rheumatic Conditions Tagged with:adalimumabJIAjuvenile idiopathic arthritis (JIA)Uveitis

Ixekizumab vs. Adalimumab for PsA: How Do They Compare?

Michele B. Kaufman, PharmD, BCGP  |  July 1, 2019

In a study of bDMARD-naive patients with active PsA and skin disease, ixekizumab proved more efficacious than adalimumab…

Filed under:Biologics/DMARDsConditionsDrug UpdatesEULAR/OtherMeeting ReportsPsoriatic Arthritis Tagged with:adalimumabEULARixekizumabPsoriatic Arthritis

The Rescue: Moving RA Patients from Adalimumab to Baricitinib

Lara C. Pullen, PhD  |  June 25, 2019

The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…

Filed under:ConditionsRheumatoid Arthritis Tagged with:adalimumabbaricitinibRheumatoid Arthritis (RA)washout

  • 1
  • 2
  • 3
  • …
  • 38
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences